2023 World Conference on Lung Cancer (Posters)-EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer

EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the feasibility and safety of adjuvant chemotherapy using nanoparticle albumin-bound paclitaxel (nab-PTX) and carboplatin (CBDCA) in patients with stage IB non-small cell lung cancer (NSCLC) following surgical resection. The primary endpoint was the completion rate of chemotherapy, and secondary endpoints included relapse-free survival (RFS), overall survival (OS), and safety. The study included 35 patients from seven Japanese institutes who received nab-PTX and CBDCA every 21 days for four cycles. The completion rate of the four-cycle chemotherapy was 75.8%. Reasons for therapy discontinuation included patient refusal, neutropenia, diarrhea, diverticulitis, and pyothorax. The five-year RFS and OS rates were 93.7% and 90.9%, respectively. Hematological and non-hematological toxicities were evaluated, with high incidence rates of leukopenia, neutropenia, and anemia, particularly grade 3/4 leukopenia. The completion rate of adjuvant chemotherapy using nab-PTX and CBDCA was lower than expected due to the high morbidity of neutrophilia. However, once the side effects were overcome, the five-year RFS and OS rates were good. This study provides important information on the use of adjuvant chemotherapy for early-stage NSCLC and the potential challenges associated with its administration.

Asset Subtitle

Yamato Motooka

Meta Tag

Speaker Yamato Motooka

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

adjuvant chemotherapy

nanoparticle albumin-bound paclitaxel

carboplatin

stage IB non-small cell lung cancer

surgical resection

completion rate

relapse-free survival

overall survival

safety

Japanese institutes